Q2 2025 Revenue Guidance: $95 million to $120 million. Emergent BioSolutions Inc (NYSE:EBS) delivered on their revenue and adjusted EBITDA targets for Q1 2025, improving their cash and liquidity ...

TRAIL-LINK’s latest development is another feather in the cap for this growing brand. TRAIL-LINK has softly begun delivering its latest, game-changing EBS Tester: a multi-testing tool developed for ...

additional_iam_policies_arns The EBS CSI driver controller's additional policies to allow more actions (kms, etc) list(string) [] no ...

The U.S. Army is rolling out its latest and greatest business system modernization program: the Enterprise Business Systems – Convergence (EBS-C). Think of it as a corporate makeover show ...

Aim. Squamous cell carcinoma (SCC) is the most common malignancy of the larynx, associated with alcohol and tobacco consumption. Acantholytic SCC (ASCC) is a rare histopathologic variant of SCC, which ...

14. Which subtype of EBS leads to a higher risk of developing SCC? a) Superficial EBS; b) Localized EBS; c) Lethal acantholytic EBS; d) EBS-DM. 15. It is correct to state the following about ...

The Enterprise Business Systems – Convergence (EBS-C) project management office (PMO) at U.S. Army Program Executive Office Enterprise Information Systems (PEO EIS) has a pivotal year ahead.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address ...

乙撑双硬脂酸酰胺（EBS）。EBS作为润滑剂，内外润滑效果极佳，与其他润滑剂如高级醇、脂肪酸酯、硬脂酸酯钙及石蜡等合用具有良好的协同作用。 EBS分子结构中,两端为非极性长链烷基,中间是极性双酰胺基,这种对称中位极性结构,赋予EBS优良的润湿和渗透能力 ...